Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 15/20 | 0.60 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22365610 | 0.84 | FDPS (0.43) | FDPSSMPD1MEN1KMT2AGPR132 | |
| SCHEMBL20377234 | 0.81 | FDPS (0.48) | FDPS | |
| SCHEMBL7784532 | 0.81 | FDPS (0.52) | FDPSMEN1KMT2ACA9CA12 | |
| SCHEMBL26697665 | 0.77 | MEN1 (0.59) | SMPD1MEN1KMT2A | |
| SCHEMBL20377242 | 0.76 | FDPS (0.56) | FDPSSMPD1 | |
| SCHEMBL20377216 | 0.76 | FDPS (0.59) | FDPSCA12MMP8 | |
| SCHEMBL25674573 | 0.76 | FDPS (0.45) | FDPS | |
| SCHEMBL15163917 | 0.75 | FDPS (1.00) | FDPSCA9CA12MMP8MMP14 | |
| SCHEMBL25682049 | 0.75 | MEN1 (0.44) | SMPD1MEN1KMT2A | |
| SCHEMBL31336089 | 0.75 | MAOB (0.50) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367283-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2025-12-04 | — | — | US | disclosed |
| EP-3348269-B1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | UNIV TSINGHUA (CN) | 2023-11-15 | — | — | EP | disclosed |
| EP-3348269-B1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | UNIV TSINGHUA (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20210008084-A1 | MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | TSINGHUA UNIVERSITY (CN) | 2021-01-14 | — | — | US | disclosed |
| EP-3698797-A1 | MEVALONIC ACID PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | Tsinghua University (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| WO-2019076269-A1 | MEVALONIC ACID PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | 清华大学 | 2019-04-25 | — | — | WO | disclosed |
| EP-3348269-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | Tsinghua University (CN) | 2018-07-18 | — | — | EP | disclosed |
| EP-3348269-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | Tsinghua University (CN) | 2018-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | GGPS1, HMGCR, COASY | FDPS 4/4885SMPD1 606/4885MEN1 3545/4885 |
| US-20250367283-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | FDPS 4/4885SMPD1 652/4885MEN1 3454/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | FDPS 4/4885SMPD1 625/4885MEN1 3542/4885 |
| US-20210008084-A1 | MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | PDCD1, CD274, PDCD5 | FDPS 16/4885SMPD1 319/4885MEN1 755/4885 |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | FDPS 4/4885SMPD1 654/4885MEN1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.